Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
-2.69% $1.810
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 29.04 mill |
EPS: | -2.25 |
P/E: | -0.800 |
Earnings Date: | Mar 27, 2024 |
SharesOutstanding: | 16.04 mill |
Avg Daily Volume: | 0.237 mill |
RATING 2024-03-28 |
---|
C+ |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | n/a | n/a | n/a | |||
Gr.Profit | n/a | n/a | ||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.800 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.14x |
Company: PE -0.800 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-0.122 (-106.73%) $-1.932 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 1.551 - 2.11 ( +/- 15.25%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-22 | Groenewald Ferdinand | Buy | 0 | |
2024-01-20 | Hogue Dale Curtis Jr. | Buy | 600 000 | Employee Stock Option (right to buy) |
2023-12-29 | Hogue Dale Curtis Jr. | Buy | 150 000 | Employee Stock Option (right to buy) |
2023-12-29 | Hogue Dale Curtis Jr. | Buy | 41 667 | Employee Stock Option (right to buy) |
2023-12-29 | Hogue Dale Curtis Jr. | Buy | 0 |
INSIDER POWER |
---|
96.29 |
Last 87 transactions |
Buy: 16 191 500 | Sell: 2 243 866 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.810 (-2.69% ) |
Volume | 0.0702 mill |
Avg. Vol. | 0.237 mill |
% of Avg. Vol | 29.66 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:32 | sell | $2.37 | N/A | Active |
---|
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.